Assam signs ₹600 cr deal for India's first state-run Proton Beam Therapy Centre
Synopsis
Key Takeaways
A cancer patient in Guwahati today stands closer to receiving the kind of precision tumour treatment previously available only in a handful of elite private hospitals in India's biggest metros. The Chief Minister's Office of Assam announced on 31 October 2026 that the Government of Assam has signed a landmark agreement with IBA Particle Therapy India Pvt. Ltd. in Guwahati to establish a Proton Beam Therapy Centre at an estimated cost of ₹600 crore — making it India's first such centre set up through a state government initiative.
What proton therapy means for patients in the Northeast
Proton Beam Therapy is not a marginal upgrade — it is a fundamentally different weapon against cancer. Unlike conventional radiotherapy, which deposits radiation energy along its entire path through the body, a proton beam can be tuned to release the bulk of its energy precisely at the tumour site, dramatically reducing damage to surrounding healthy tissue. For paediatric cancers, brain tumours, and cases near critical organs, that precision can mean the difference between cure and serious long-term side effects.
Northeast India carries one of the country's highest age-adjusted cancer incidence burdens for several cancer types, yet patients requiring advanced radiation oncology have historically had to travel to Chennai, Mumbai, or Delhi — a journey that is financially and logistically punishing for most families in the region. The new centre, once operational, would serve not only Assam's own population but also patients from neighbouring northeastern states and, as the announcement notes, from neighbouring countries — a quiet acknowledgement of Assam's geographic role as a healthcare hub for Bangladesh, Bhutan, and Myanmar.
IBA Particle Therapy: the Belgian firm behind the deal
IBA Particle Therapy India Pvt. Ltd. is the Indian subsidiary of Ion Beam Applications (IBA), a Belgian company that is among the world's leading designers and installers of proton therapy systems. The agreement was signed in the presence of Chief Minister Dr. Himanta Biswa Sarma, signalling the political weight the state government is placing on this project.
Since taking office in 2021, Dr. Sarma has pushed an aggressive expansion of Assam's tertiary healthcare footprint — new medical colleges, upgraded district hospitals, and satellite facilities linked to national institutions. The proton centre represents the most capital-intensive single health infrastructure commitment of that run, and its public-funding model sets it apart from the handful of proton centres that exist or are planned in India under private-sector ownership.
A state-led bet on precision oncology
Across India, a quiet shift is under way: several state governments have begun signing direct technology-transfer agreements with global medical equipment firms rather than waiting for central institutes or private hospital chains to fill the gap. Assam's move is the most explicit example yet of a state anchoring high-end oncology infrastructure with public money in a region that private capital has largely bypassed.
The ₹600 crore facility is also expected to seed an ecosystem. The announcement specifically flags new opportunities in medical physics, radiation oncology, and cancer research — disciplines that require specialist training pipelines and could, over time, position Guwahati as a regional centre for oncology education alongside treatment.
Key questions remain open: the construction timeline, how medical physics and oncology teams will be recruited and trained, and whether the centre will eventually tie into national research bodies such as the Department of Atomic Energy, which oversees India's existing proton and heavy-ion research programmes. Those answers will determine whether the ₹600 crore translates into a functioning, staffed facility within a realistic window — or becomes another ambitious headline waiting for follow-through.
For now, the signing marks a clear inflection point. The Northeast has waited long enough for cancer care that doesn't begin with a one-way ticket out of the region.